Welcome to the e-CCO Library!

P403: Treatment naïve newly diagnosed patients with Crohn's disease have microbial dysbiosis correlated with disease activity and faecal calprotectin—results from a prospective inception cohort
Year: 2018
Source: ECCO '18 Vienna
Authors:

H. Yanai1,2*, I. Goren3,4, L. Reshef5, L. Godny1,2, K. Yadgar1, K. Zonenesain1, I. Dotan2,3

Created: Thursday, 21 February 2019, 9:14 AM
P404 Prolonged steroid exposure prior to admission is associated with increased likelihood of rescue therapy and colectomy in acute severe ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Barnes1,2, P. Spizzo1

Created: Thursday, 30 January 2020, 10:12 AM
P404: Development of anti-drug antibodies among those treated with adalimumab and ABP 501 and its impact on serum drug concentration in randomised controlled studies
Year: 2018
Source: ECCO '18 Vienna
Authors:

V. Chow*, A. Kaliyaperumal, N. Zhang, J. Miller, D. Mytych, M. Starcevic Manning, I. Wala, H. Wang, E. Krishnan

Created: Thursday, 21 February 2019, 9:14 AM
P404: Healthcare utilization and expenditures for patients with Ulcerative Colitis on advanced therapies in Germany
Year: 2021
Source: ECCO'21 Virtual
Authors: Picker, N.(1);Bokemeyer, B.(2);Wilke, T.(3);Rosin, L.(4);Patel, H.(5);
Created: Wednesday, 2 June 2021, 4:12 PM
P404: Persistence of subcutaneous infliximab after switching from intravenous in a French national cohort of IBD patients in remission
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Mathieu, N.(1)*;Riviere, P.(2); Heluwaert, F.(3); Hébuterne, X.(4);Chupin, A.(5);Bouguen, G.(6);Vuitton, L.(7);Allez, M.(8);Montuclard, C.(9);Nachury, M.(10);Nancey, S.(11);Amélie, B.(12); Gilletta, C.(13);Abitbol, V.(14);Altwegg, R.(15);de Maissin, A.(16);Plastaras , L.(17); Ah Soune, P.(18);Boureille, A.(19);Bouhnik, Y.(20);Seksik, P.(21);Chanteloup, E.(22);marion, S.(23);Uzzan, M.(24);Andrau, P.(25);Rouillon, C.(26);Arondel, Y.(27);Peyrin Biroulet, L.(28);Laharie, D.(29);
Created: Friday, 14 July 2023, 11:05 AM
P404: Real-life experience with golimumab in ulcerative colitis patients according to prior anti-TNF use
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

C. Taxonera*1, F. Bertoletti2, C. Rodriguez3, I. Marin4, J. Arribas5, P. Martinez-Montiel6, M. Sierra7, L. Arias8, M. Rivero9, A. Juan10, E. Iglesias11, N. Manceñido12, J.L. Perez-Calle13, A. Algaba14, M. Barreiro-de Acosta15, A. Gutierrez16, F. Argüelles17, D. Busquets18, M. Chaparro19, C. Alba1, D. Olivares1, M. Calvo20, J.P. Gisbert19

Created: Friday, 22 February 2019, 9:49 AM
P404: Stopping 5-aminosalicylates in Crohn’s disease patients starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. Ungaro*1, B. Limketkai2, C. B. Jensen3, C. Yzet4, K. H. Allin3, M. Agrawal5, J. Burisch3, T. Ullman6, T. Jess3, J-F. Colombel1

Created: Friday, 22 February 2019, 9:41 AM
P404: Underrepresentation of minorities and lack of race reporting in ulcerative colitis drug development clinical trials
Year: 2022
Source: ECCO'22
Authors: Sedano, R.(1,2);Hogan, M.(3);McDonald, C.(4);Aswani-Omprakash, T.(5);Ma, C.(2,6);Jairath, V.(2,7);
Created: Friday, 11 February 2022, 3:52 PM
P404: Vaccinations and immunization status in Paediatric inflammatory bowel disease: data from the VIP IBD study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Martinelli M.*1, Strisciuglio C.2, Giugliano F.P.3, Urbonas V.4, Serban D.5, Banaszkiewicz A.6, Assa A.7, Drskova T.8, Hojsak I.9, Navas Lopez V.M.10, Romano C.11, Sladek M.12, Aloi M.13, Kucinskiene R.14, Staiano A.15, Miele E.15 ESPGHAN Open IBD Interest Group16

Created: Wednesday, 20 February 2019, 10:36 AM
P405 Comparison of long-term outcomes of infliximab vs. adalimumab in 1488 biologic-naive Korean patients with Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

Y.S. Jung Prof. Dr.1, M. Han2, S. Park3, J.H. Cheon4

Created: Thursday, 30 January 2020, 10:12 AM
P405: 5-ASA prescription trends over time in inflammatory bowel disease 1996 to 2015–A UK population-based study
Year: 2018
Source: ECCO '18 Vienna
Authors:

V. Jairath1,2*, S. Hokkanen3, L. Guizzetti2, N. Boxall3, S. Campbell-Hill4, H. Patel4

Created: Thursday, 21 February 2019, 9:14 AM
P405: Development and validation of a rapid immunoassay for monitoring of ustekinumab concentrations in Inflammatory Bowel Disease patients
Year: 2021
Source: ECCO'21 Virtual
Authors: Thomas, D.(1);Compernolle, G.(1);Guedelha Sabino, J.P.(2,3);Ferrante, M.(2,3);Vermeire, S.(2,3);Declerck, P.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P405: Infliximab trough level measured during treatment induction may be predictive of the loss of response to Infliximab during treatment maintenance in inflammatory bowel disease patients: a longitudinal observational retrospective study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

C. Liefferinckx*1, C. Minsart2, A. Cremer1, L. Amininejad1, J.-F. Toubeau3, E. Quertinmont2, J. Deviere1, A. Van Gossum1, D. Franchimont1

Created: Friday, 22 February 2019, 9:49 AM
P405: Long-term safety of 3 years of ozanimod in moderately to severely active ulcerative colitis: an interim analysis of the True North open-label extension
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Panaccione, R.(1)*;Danese, S.(2);Wolf, D.C.(3);Canavan, J.B.(4);Jain, A.(4);Wu, H.(4);Petersen, A.(4);Charles, L.(4);Afzali, A.(5);Abreu, M.T.(6);
Created: Friday, 14 July 2023, 11:05 AM
P405: Primary non-response and loss-of-response to first-line biological therapies are more common in patients with Ulcerative Colitis than Crohn’s Disease – preliminary results from the Danish IBD Biobank Project
Year: 2022
Source: ECCO'22
Authors: Zhao, M.(1);Larsen, L.(2);Dige, A.(3);Hvas, C.L.(3);Poulsen, A.(4);Christiansen, D.(4);Attauabi, M.(1,5);Lo, B.(1);Wewer, M.(1,6);Ovesen, P.D.(6);Petersen, A.M.(1,7);Bendtsen, F.(1);Seidelin, J.B.(5);Burisch, J.(1,4);
Created: Friday, 11 February 2022, 3:52 PM
P405: Sustainability of biologic therapies is less in UC than CD patients independent of prior biologic experience
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Doherty*1, M. Buckley1, G. Cullen1, D. Keegan1, K. Byrne1, G. Horgan1, H. Mulcahy1, J. Sheridan1, G. A. Doherty1,2

Created: Friday, 22 February 2019, 9:41 AM
P405: Toxicity of thiopurines in patients with inflammatory bowel disease: inventory and predictive factors
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Labidi A., Serghini M., Ben Mustapha N., Fekih M., Boubaker J., Filali A.

Created: Wednesday, 20 February 2019, 10:36 AM
P406 Adherence, acceptability and serum trough concentration of adalimumab autoinjector in quiescent patients with inflammatory bowel diseases
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Kato, N. Yamaga, A. Ishibashi, K. Kani, S. Nagoshi

Created: Thursday, 30 January 2020, 10:12 AM
P406: A retrospective analysis of the efficacy of vedolizumab on extra-intestinal manifestations in patients with inflammatory bowel disease across five European countries
Year: 2021
Source: ECCO'21 Virtual
Authors: Kopylov, U.(1);Burisch , J.(2); Ben-Horin , S.(1);Braegger, F.(3);Fernández-Nistal , A.(4);Lara, N.(5);Vavricka , S.(6,7);
Created: Wednesday, 2 June 2021, 4:12 PM
P406: AlphaE+ cells have increased expression of inflammatory markers and are correlated in the ileum and colon
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

R. Ichikawa1, J. Eastham-Anderson1, A. Scherl1, J. Hackney1, L. Orozco1, W. Faubian2, J. Mansfield3, 4, J. Kirby3, C. Lamb3, 5, M. Keir*1

Created: Friday, 22 February 2019, 9:49 AM